Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VNN1 | O95497 | 2/20 | 0.34 |
| ▸ | ELANE | P08246 | 6/20 | 0.33 |
| ▸ | GPBAR1 | Q8TDU6 | 6/20 | 0.32 |
| ▸ | TACR1 | P25103 | 1/20 | 0.32 |
| ▸ | CCR2 | P41597 | 1/20 | 0.32 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.32 |
| ▸ | BRAF | P15056 | 3/20 | 0.32 |
| ▸ | RAF1 | P04049 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2206917 | 1.00 | VNN1 (0.34) | VNN1ELANEGPBAR1TACR1CCR2 | |
| SCHEMBL14174391 | 0.93 | VNN1 (0.33) | VNN1ELANEGPBAR1BRAFRAF1 | |
| SCHEMBL2210261 | 0.92 | KDM4E (0.35) | VNN1ELANEP2RX3BRAF | |
| SCHEMBL2210254 | 0.92 | KDM4E (0.35) | VNN1ELANEP2RX3BRAF | |
| SCHEMBL12060218 | 0.89 | ALDH1A1 (0.37) | VNN1ELANEP2RX3 | |
| SCHEMBL2212531 | 0.87 | VNN1 (0.33) | VNN1GPBAR1BRAFRAF1 | |
| SCHEMBL2212537 | 0.87 | VNN1 (0.33) | VNN1GPBAR1BRAFRAF1 | |
| SCHEMBL2206914 | 0.85 | VNN1 (0.34) | VNN1ELANEGPBAR1 | |
| SCHEMBL2209792 | 0.84 | MAPK14 (0.36) | ELANEP2RX3 | |
| SCHEMBL2209797 | 0.84 | MAPK14 (0.36) | ELANEP2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110319614-A1 | Organic Compounds | NOVARTIS AG (CH) | 2011-12-29 | — | — | US | claimed |
| EP-2099769-B1 | 6-OXO.-1, 6-DIHYDROPYRIMIDIN-2-YLS IN THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2011-07-27 | — | — | EP | claimed |
| US-20100249405-A1 | Organic Compounds | NOVARTIS AG | 2010-09-30 | — | — | US | claimed |
| US-20110319614-A1 | Organic Compounds | NOVARTIS AG (CH) | 2011-12-29 | — | — | US | disclosed |
| US-8048886-B2 | Substituted pyrazine-3-one-derivatives as IAP inhibitors | NOVARTIS AG (CH) | 2011-11-01 | — | — | US | disclosed |
| US-20100249405-A1 | Organic Compounds | NOVARTIS AG | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319614-A1 | Organic Compounds | XIAP, BIRC5, BIRC3 | VNN1 4396/4885ELANE 592/4885GPBAR1 601/4885 |
| US-20100249405-A1 | Organic Compounds | XIAP, BIRC5, BIRC3 | VNN1 4396/4885ELANE 592/4885GPBAR1 601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.